Health Care • Biotechnology: Pharmaceutical Preparations
$1.95 ▲ +0.16
(+8.94%)
MKT CAP: $19.6M • VOL: 78.5K
52W L $2 52W H $30
ROARABLE / RQD
D+ • 54/100
PIOTROSKI
5 / 9
MCRB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $789.0K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$94.0M | -$121.3M | -$195.1M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | $5.7M | $136.0K | -$113.7M |
| EBITDA (Normalized) | -$93.8M | -$121.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.1M | -$148.6M | -$117.4M |
| Capital Expenditures (CapEx) | $252.0K | $380.0K | — |
| Free Cash Flow (FCF) | $865.0K | -$149.0M | -$117.4M |
| FCF Margin % | 80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $45.8M | $30.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $44.2M | $13.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MCRB.